Risk factors
Artivion (AORT) risk factors
Item 1A of every Artivion, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors34 risks1 new4 reworded
A new U.S. healthcare and tax law creates uncertainty around corporate taxes, deductions, and healthcare programs.
Filed Feb 18, 2026 - FY2024 10-K risk factors33 risks
Artivion relies heavily on tissue preservation services, BioGlue, aortic stent grafts, and On-X products for its revenues. Operations face strict regulatory scrutiny regarding medical devices, human tissues, and sterilization processes like EtO. Growth depends on ongoing clinical studies, regulatory approvals, and international expansion.
Filed Feb 28, 2025